Comparison · NCT03237481-769d8897
Treatment Group 1: HTX-011 vs Treatment Group 2: Bupivacaine HCI: Percetange of Subjects Who Are Opioid-free for HTX-011 Compared With Bupivacaine HCl.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Treatment Group 1: HTX-011 vs Treatment Group 2: Bupivacaine HCI: Percetange of Subjects Who Are Opioid-free for HTX-011 Compared With Bupivacaine HCl. Trial comparisons, record NCT03237481-769d8897. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03237481-769d8897
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.512 | 0.436 | 0.588 | wilson | |
| Risk in group 2 | 0.401 | 0.331 | 0.476 | wilson | |
| Risk difference, group 1 minus group 2 | 0.111 | 0.00458 | 0.214 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.28 | 1.01 | 1.62 | log | |
| Odds ratio, group 1 over group 2 | 1.57 | 1.02 | 2.41 | log | |
| Number needed to treat, for one more participant with the outcome on Treatment Group 1: HTX-011 than on Treatment Group 2: Bupivacaine HCI | 9.01 | 4.67 | 218 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Treatment Group 1: HTX-011 | HTX-011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation. | 84 | 164 | OG000 |
| Group 2 | Treatment Group 2: Bupivacaine HCI | Bupivacaine HCl without epinephrine, 75 mg by injection. | 69 | 172 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Percetange of Subjects Who Are Opioid-free for HTX-011 Compared With Bupivacaine HCl.
- Description
- Time frame
- 72 hours
- Population
- ITT Population.
Source ClinicalTrials.gov
Trial
- Title
- Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)
- NCT number
- NCT03237481
- Phases
- PHASE3
- Conditions
- Postoperative Pain
- Interventions
- HTX-011, Bupivacaine HCl, Saline placebo, Luer-lock applicator, Vial access device
- Lead sponsor
- Heron Therapeutics
- Results first posted
- 2021-10-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03237481?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03237481-769d8897